+7 (495) 505-52-05

" "





2013-06-04 20:44:47

. . . , . 250 . 2 . (34), , 500 . 2 . - ? ....
2013-05-15 20:22:14

10. 20. ? ...
2013-05-05 12:39:07

! 4 , , - , ?...
2013-04-24 10:50:26

! : , . : + + . , , , . 2- . - , . . . 3 ......
2013-04-18 21:36:56

! . 50 . . : - , - , . . . - . - , , . , . . ......

,
:

. ""

HEADING_TITLE_2
?
?-
- / 40
- / 2 N5 -
??
400 N10 Lek
250+62 5/5 25 100 / / Lek
27 5/ 120 Glaxo Operations UK Limited
400+57/5 17 5 70 / / Lek
- / 50 Pierre Fabre Dermo-Cosmetique
400+57/5 35 140 / / Lek
- 100 Pierre Fabre Dermo-Cosmetique
500+125 N15 Lek
/ 50 Pierre Fabre Dermo-Cosmetique
875+125 N14 Lek
30 Pierre Fabre Dermo-Cosmetique
250+62 5 N20 Lek
8451/8651 AVENT ISIS
500+125 N14 Lek
/ 80021 (SCF560/17) 125 Philips
875+125 N14 Lek
1 82820 (SCF632/27) N2 Philips
250 N16
3 80600 (SCF635/27) N2 Philips
250/5 40 / /
3 82830 (SCF633/27) N2 Philips
1000 N12 Sandoz GmbH
- / 86395 (SCF185/00) Philips
500 N12 Sandoz GmbH
/ 0-6 (SCF699/17) 60 Philips
1 25 N30
/ / 86485 (SCF690/27) 125 N2 Philips
10 N30
6 80540 (SCF654/27) N2 Philips
2 5 N30
/ 6-12 80560 (SCF656/27) N2 Philips
5 N30
/ 80510 (SCF651/27) N2 Philips
TVY-120 Amrus
1 80520 (SCF652/27) N2 Philips
AMDT10 Amrus
3 80530 (SCF653/27) N2 Philips
AMDT11 Amrus
/ 86360 (SCF894/01) 3 Philips
AMDT13 Amrus
/ 86330 (SCF884/01) 3 Philips
AMDT-14L Amrus
0-2 81500 (SCF151/00) N1 Philips
500 N20
/ 6 86125 (SCF172/15) Philips
500/ 2 N10 - / /
/ 6 86124 (SCF172/14) Philips
- N20
6-18 83520 (SCF182/24) N2 Philips
10 N112
6 86460 (SCF176/22) N2 Philips
10 N56
- N20 /
40 N112
50 N10
25 Zambon S P A
50 N5
25 /
/ 300 &
N20 / /
150 &
25 N30
/ 300 &
5 N12 / - /
/ 300 &
5 N12 / - /
0 5 N30 GlaxoSmithKline
5 N12 / - /
0 5 N90 GlaxoSmithKline
5 N12 / - / -
300 N60
5 N12 / - /
350 N48
5 N24 / - /
0 1% 30 / Ranbaxy
5 N24 / - /
500 N20
5 N24 / - /
0 1% 15 Bayer HealthCare Manufacturing S r L
5 N24 / - / -
0 1% 15 Bayer HealthCare Manufacturing S r L
5 N24 / - /
0 1% 15
5 N3 / - /
0 1% 20 Bayer HealthCare Manufacturing S r L
5 N3 / - /
0 1% 50 Bayer HealthCare Manufacturing S r L
5 N3 / - /
20 N30
5 N3 / - / -
/ 8
5 N3 / - /
N8
5 N6 / - /
- N20
5 N6 / - /
N20
5 N6 / - / -
100 -
5 N6 / - /
5
N20
50 N50
250 N20
25 N50 -
50 N20
15% 30 /
N24 / Dr Theiss Naturwaren GmbH
20% 30 / Ranbaxy
0 255 / 15 (88) /
100/5 N1 / -
0 255 / 30 (176) /
200/5 N1 / -
- N50 / Biologische Heilmittel Heel GmbH
250 N6 -
N60
500 N2 -
100 N100 -
500 N3 -
50+450 N30
125 N6
50+450 N60
200/5 16 5 / /
CN-232 / A&D Company Ltd
500 N3
CN-233 A&D Company Ltd
1% 5
DT-635 A&D Company Ltd
75
DT-624 A&D Company Ltd
- 30
DT-624 A&D Company Ltd
- / N1 ()
DT-624 A&D Company Ltd
/ 2 7 Dr Theiss Naturwaren GmbH
UA-604 A&D Company Ltd
10 N30 Merz Pharma GmbH & Co KGaA
UB-201 A&D Company Ltd
10 N90 Merz Pharma GmbH & Co KGaA
N10 - - ( )
20 N28 Merz Pharma GmbH & Co KGaA
N20 - - ( )
10 /
N60
30
N10
/ 50
N28 Bayer Bitterfeld GmbH
/ 150
50
/ 50
800+40 N12 SEQUEL PHARMACEUTICALS
30
800+40 N24 SEQUEL PHARMACEUTICALS
30 / /
- 25 / HERKEL B V
30
- N20 / HERKEL B V
/ + N30
- N24
( ) 20
N10 / - / / -
10 / Medana Pharma
N10 /
10% 10 - /
N10 /
15 Laboratories CHEMINEAU
N10 /
150 Laboratories CHEMINEAU
N10 /
+ 50 SE
N3 / - / / -
+ 125 SE
N30 /
125 Laboratories CHEMINEAU
- N20
150 Laboratories CHEMINEAU/
- N12 / - / / -
50 Laboratories CHEMINEAU/
- N12 / - / /
50 SE/
- N12 / - /
0 65% 50
- N6 / - / / -
150
- N6 / - / /
/ 75
- N6 / - /
/ 75
N4
- 20
500 N6 -
6 50
N100
6 ()
N5 / - / /
3-5 50
N10
3-5 & --
20 /
2 50
10 N25
N200 Cotton Club
10 N50
-
- N6
- - N50
100 N20
- - N502
N2 02702
-

- - N50
10+150 N28 -
- N25
10+300 N28 -
- /
5+150 N28 -
10 N30 Pfizer
5+300 N28 -
20 N30 Pfizer
150 N14
16 N30
150 N28
8 N30
300 N14
0 05% 15 /
300 N28
0 05% 15 /
20 N30
0 05% 30 /
25
15 /
100 N10 -
15 /
100 N20 -
30 /
100 N40 -
15 /
50 N10 -
15 /
50 N20 -
30 /
200 N10 -
30 /
2% 15
15 /
2 5 N30 Servier Laboratoires
30 /
1 5 N30 Servier Laboratoires
2 5%+2 5% 5 //
120 N7 Merck sharp & dohme
20 N50 -
30 N28 Merck sharp & dohme
250
60 N14 Merck sharp & dohme
/ 1010 N10
60 N28 Merck sharp & dohme
0 007% 5
90 N28 Merck sharp & dohme
30 Merckle
90 N7 Merck sharp & dohme
- 5 N2
C 5 N20 Nutrilo GmbH DE
25 N10
45 / Laboratoires Boiron
25 N10
30
25 N10
4 N30
25 N10
- 10
/ 30 Tekmar Slovensko s r o
- 10
/ / 30 Tekmar Slovensko s r o
- 0 5 N30
30 Tekmar Slovensko s r o
100/ 1 N10 - /
30 Tekmar Slovensko s r o
100/ 2 N10 - /
30 Tekmar Slovensko s r o
N120
60
N60
17
N60
17
- 20
17
- N36
60
- - 35
60
51 N120 Sole Pharmaceuticals Ltd
17
51 N60 Sole Pharmaceuticals Ltd
60
15% 25 /
60
320 N10
60
5% 50 /
10 N5 -
50 N30
2 N25 - /
5 N60
2 N25 - / 1/25
N30 Softgel Healthcare Private Limited
40/ 5 N5 - /
N100 /
N50
0 5 N60
100/ 10 - / /
50
100/ 3 N5 - / /
5/ 5
/ Q10 - 10 N3
- 2 N20 /
/ - 10 N3
- 50
0 5 N30
200 N20 -
0 4% 5
N10 -
/ 20
50 N28
/ 75
/ 10
- 50
3 50
- 50
75
2% 60 /
4 8 50
5% 60 /
/ 150
- / 200
75
/ 150
75
/ 6 N2
75
/ 100
75
- / N60
/ 250
/ 250
75
250
75
/ 250
/ N10
// 250
/ N10
/ 250
/ N10
250
/ N10
250
/ N10
(L)
/ N10
(XL)
/ N10
(M)
/ N10
(L)
/ N10
(M)
N10 -
(L)
N10 -
10 N28
50 N200
40
250 () N200 -
- N10 Bayer Bitterfeld GmbH
2 5
25 N30
100+877 N20
0 05% 6
100
0 14/ 10
200
10
N10
4
N20
100 N50
N50
- 100 N50
- N10 -
- 300 N30
- N20 -
- N24
N56
10 N10 / -
30
170 / -
10
10 N10 / -
10
170 -
10
10 N10 / -
10
170 / -
10
10 N28 Actavis Group
10
4 N28 Actavis Group
10
5 N28 Actavis Group
100 N30
5 N98 Actavis Group
- N10 Bayer Bitterfeld GmbH
1 N10
75
50
30
100 N20
16 N28 Astrazeneca
250
32 N28 Astrazeneca
125
8 N28 Astrazeneca
125
16+12 5 N28 Astrazeneca
150
25 N25 UCB Pharma S A
75
100 N30
150
50 N30
50 N60
100 N30
N60
50 N30
N60
250 N30
/ N60
250 N60
/ (3-7 ) N60
N30
N60
/ / 100
N60
46
N60
10 N30
N60
10 N30
/ (1-3 ) N45
20 N30
N120
20 N30
N60
20 N30
/ (7-14 ) N60
20 N90
N60
40 N30
N60
10 N30
160/ 5 (60 ) / 3M
- 10 N60
- 1-3
- 10 N30 Teva
1 5
10 N30
N3 (27)
10 N90
3- 0 25 N30
20 N30
3- 0 25 N60
40 N30
3- 0 5 N60
0 25/ 20 - /
3- 1 N30
10+40 N28
200 N12
5+20 N28
200 N36
5+40 N28
0 15% 5
200+28 5/5 7 7 (70) / / GlaxoSmithKline
/ 25
250+125 N20 SmithKline Beecham Pharmaceuticals
2 N30 -
400+57/5 12 6 (70) / / GlaxoSmithKline
2 N90 -
500+125 N14 SmithKline Beecham Pharmaceuticals
4 N30 -
20
4 N90 -
N100 /
2+500 N30
N100 /
7 5/ 100 - / Merckle
N24 Richard Bittner AG
7 5/ 40 - / Merckle
N48 Richard Bittner AG
3/ 100
10 N60 -
6/ 100
0 05% 15
- 7 5 / 2 N20 - /
0 05% 15
10 N30
/ 20 Laboratoire De La Mer
250
() 75 Laboratoire De La Mer
- 100
BB- / 50
100
/ 30 Kotemein international biotechnology Co
250
/ - 30 Kozas kozmetik Kimya end Ve Tic A S
50
/ / 30 Kotemein international biotechnology Co
N100
/ 30 Kotemein international biotechnology Co
905
/ / 30 Kotemein international biotechnology Co
1% 30
/ 30 Kotemein international biotechnology Co
1% 50
/ 50
10/ 1 5 N10 - /
- 45 Kozas kozmetik Kimya end Ve Tic A S
10/ 1 5 N3 - /
/ / 30 Kotemein international biotechnology Co
10/ 1 5 N5 - /
/ / 30 Kotemein international biotechnology Co
15 N10
/ / 75
15 N20
/ / 30 Kotemein international biotechnology Co
7 5 N20
/ / 30
100 N2
50 N30
100 N6
80 Montavit Pharmazeutische Fabrik GmbH
50 N2
400 N1 - /
50 N6
500 N10
250 N20
500 N10 -
125 N10 -
500 N20
125 N6 -
- 200 N20 Merckle
60 N10 -
- 600 N10 Merckle
250 N100
- N50
- 25 N50
5% 5 Sandoz d d
5 N30
5% 5
10 N20
5% 2 /
10 N30
400 N20
10 N60
- 200 N20
5 N20
- 400 N20
5 N30
- 5% 5 /
5 N60
N10
- 5 N30 Zentiva a s
N30
- 5 N30 Lek
/ 10 N10 Erbozeta S p A
- 10 N30 Teva Pharmaceutical Works Private Co
/ 10 N5
- 5 N30 Teva Pharmaceutical Works Private Co
/ 4 5
10 N30 -
100 100 N20 Sandoz D D
5 N30 -
100 N20 / - / Sandoz D D
10% 25 -
200 200 N20 Sandoz D D
10% 40 - /
200 N20 / - / Sandoz D D
10% 40 - /
20/ 100 Pharma Wernigerode GmbH
125+31 25/5 25 100 / / Lek